{"generic":"Meningococcal Oligosaccharide Vaccine, Diphtheria Conjugate","drugs":["Meningococcal Oligosaccharide Vaccine, Diphtheria Conjugate","Menveo"],"mono":{"0":{"id":"jx9zs0","title":"Generic Names","mono":"Meningococcal Oligosaccharide Vaccine, Diphtheria Conjugate"},"1":{"id":"jx9zs1","title":"Dosing and Indications","sub":{"0":{"id":"jx9zs1b4","title":"Adult Dosing","mono":"<ul><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (through age 55 years) 0.5 mL IM as a single dose (manufacturer dose)<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (through age 55 years with high-risk conditions) 0.5 mL IM as 2-dose series, given at least 2 months apart (guideline dose)<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (revaccination of adults who remain at increased risk for infection) 0.5 mL IM every 5 years<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (56 years or older; revaccination or person previously vaccinated with Menveo(R)) 0.5 mL IM<\/li><\/ul>"},"1":{"id":"jx9zs1b5","title":"Pediatric Dosing","mono":"<ul><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (Initiating at 2 months of age): 0.5 mL IM as a 4-dose series at 2, 4, 6, and 12 months of age (manufacturer dose)<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (initiating at 8 weeks to 6 months with high-risk conditions) 4-dose series given at 2, 4, 6, and 12 months of age (guideline dosing)<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (7 to 23 months of age with high-risk conditions and previously unvaccinated): 2 doses at least 12 weeks apart and second dose after the first birthday (guideline dosing)<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (2 years or older with high-risk conditions, who have not received a complete vaccine series): 2-dose series, given at least 8 weeks apart (guideline dose)<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (11 through 12 years) give single dose and a booster dose at age 16 years (guideline dose)<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (11 through 18 years, with HIV) 2-dose series, given at least 8 weeks apart (guideline dose)<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> Catch-up: Vaccinate at 13 to 18 years if not previously vaccinated (guideline dose)<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> Catch-up: If first dose was given at age 13 to 15 years, give booster dose at age 16 to 18 years, with at least 8 weeks between doses; if first dose is given at age 16 years or older, a booster dose is not required (guideline dose)<\/li><\/ul>"},"3":{"id":"jx9zs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Meningococcal infectious disease; Prophylaxis<br\/>"}}},"3":{"id":"jx9zs3","title":"Contraindications\/Warnings","sub":[{"id":"jx9zs3b9","title":"Contraindications","mono":"allergic reactions, severe (eg, anaphylaxis), after a previous dose of meningococcal oligosaccharide vaccine, diphtheria conjugate, any component of the vaccine or any other CRM-197 protein, diphtheria toxoid or meningococcal-containing vaccine <br\/>"},{"id":"jx9zs3b10","title":"Precautions","mono":"<ul><li>allergic reactions, acute; appropriate supportive medical treatment should be readily available during treatment<\/li><li>Guillain-Barre Syndrome (GBS) has been reported in association with administration of meningococcal quadrivalent polysaccharide conjugate vaccine<\/li><li>immunocompromised individuals, including receipt of immunosuppressive therapy; expected immune response may not be obtained<\/li><li>infants, premature; increased risk of apnea<\/li><li>syncope, sometimes associated with seizure-like activity, has been reported; monitoring recommended<\/li><li>report suspected adverse events to Novartis Vaccines at 1-877-683-4732 or to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or www.vaers.hhs.gov<\/li><\/ul>"},{"id":"jx9zs3b11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"jx9zs3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk is minimal.<br\/>"}]},"4":{"id":"jx9zs4","title":"Drug Interactions","sub":{"1":{"id":"jx9zs4b14","title":"Major","mono":"<ul><li>Cyclosporine (theoretical)<\/li><li>Measles Virus Vaccine, Live (probable)<\/li><\/ul>"}}},"5":{"id":"jx9zs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema (adult, 16%; pediatric, 11% to 28%), Injection site pain (adult, 38% to 41%; pediatric, 28% to 44%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (infants, 8% to 16%), Nausea (adult, 7% to 10%; pediatric, 8% to 12%)<\/li><li><b>Musculoskeletal:<\/b>Myalgia (adult, 14% to 18%; pediatric, 10% to 19%)<\/li><li><b>Neurologic:<\/b>Headache (adult, 25% to 30%; pediatric, 5% to 29%), Somnolence (pediatric, 12% to 50%)<\/li><li><b>Psychiatric:<\/b>Crying, excessive (infant, 21% to 41%), Irritability (pediatric, 16% to 57%)<\/li><li><b>Other:<\/b>Malaise (adult, 10% to 16%; pediatric, 11% to 14%)<\/li><\/ul>"},"6":{"id":"jx9zs6","title":"Drug Name Info","sub":{"0":{"id":"jx9zs6b17","title":"US Trade Names","mono":"Menveo<br\/>"},"2":{"id":"jx9zs6b19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"jx9zs6b20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"jx9zs7","title":"Mechanism Of Action","mono":"Vaccination with meningococcal oligosaccharide vaccine, diphtheria conjugate leads to the production of bactericidal antibodies that protects against invasive meningococcal disease.<br\/>"},"9":{"id":"jx9zs9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>for IM use only; do not give subQ, IV, or intradermally<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>reconstitute with supplied diluent, shake well to dissolve; use immediately or store below 77 F (25 C) for up to 8 hours<\/li><li>administer IM into the anterolateral aspect of the thigh (infants) or the deltoid muscle (toddlers, adolescents, adults)<\/li><li>do not mix with any other vaccine<\/li><\/ul><\/li><\/ul>"},"10":{"id":"jx9zs10","title":"Monitoring","mono":"signs\/symptoms of syncope for 15 min following administration <br\/>"},"13":{"id":"jx9zs13","title":"Clinical Teaching","mono":"<ul><li>In adolescents and adults, drug may cause injection site pain, headaches, myalgia, malaise, and nausea.<\/li><li>In infants and children, drug may cause injection site erythema\/pain, irritability, sleepiness, persistent crying, diarrhea, and vomiting.<\/li><li>Inform infant or child caregiver that receiving the entire series of vaccinations is important for effectiveness.<\/li><\/ul>"}}}